1
|
Feller SM: Crk family adaptors-signalling
complex formation and biological roles. Oncogene. 20:6348–6371.
2001. View Article : Google Scholar : PubMed/NCBI
|
2
|
Birge RB, Kalodimos C, Inagaki F and
Tanaka S: Crk and CrkL adaptor proteins: Networks for physiological
and pathological signaling. Cell Commun Signal. 7:132009.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Bos JL, Rehmann H and Wittinghofer A: GEFs
and GAPs: Critical elements in the control of small G proteins.
Cell. 129:865–877. 2007. View Article : Google Scholar : PubMed/NCBI
|
4
|
Hasegawa H, Kiyokawa E, Tanaka S,
Nagashima K, Gotoh N, Shibuya M, Kurata T and Matsuda M: DOCK180, a
major CRK-binding protein, alters cell morphology upon
translocation to the cell membrane. Mol Cell Biol. 16:1770–1776.
1996. View Article : Google Scholar : PubMed/NCBI
|
5
|
Tanaka S, Morishita T, Hashimoto Y,
Hattori S, Nakamura S, Shibuya M, Matuoka K, Takenawa T, Kurata T,
Nagashima K, et al: C3G, a guanine nucleotide-releasing protein
expressed ubiquitously, binds to the Src homology 3 domains of CRK
and GRB2/ASH proteins. Proc Natl Acad Sci USA. 91:3443–3447. 1994.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Miller CT, Chen G, Gharib TG, Wang H,
Thomas DG, Misek DE, Giordano TJ, Yee J, Orringer MB, Hanash SM and
Beer DG: Increased C-CRK proto-oncogene expression is associated
with an aggressive phenotype in lung adenocarcinomas. Oncogene.
22:7950–7957. 2003. View Article : Google Scholar : PubMed/NCBI
|
7
|
Wang L, Tabu K, Kimura T, Tsuda M, Linghu
H, Tanino M, Kaneko S, Nishihara H and Tanaka S: Signaling adaptor
protein Crk is indispensable for malignant feature of glioblastoma
cell line KMG4. Biochem Biophys Res Commun. 362:976–981. 2007.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Sriram G and Birge RB: Emerging roles for
crk in human cancer. Genes Cancer. 1:1132–1139. 2010. View Article : Google Scholar : PubMed/NCBI
|
9
|
Fathers KE, Bell ES, Rajadurai CV, Cory S,
Zhao H, Mourskaia A, Zuo D, Madore J, Monast A, Mes-Masson AM, et
al: Crk adaptor proteins act as key signaling integrators for
breast tumorigenesis. Breast Cancer Res. 14:R742012. View Article : Google Scholar : PubMed/NCBI
|
10
|
Rodrigues SP, Fathers KE, Chan G, Zuo D,
Halwani F, Meterissian S and Park M: CrkI and CrkII function as key
signaling integrators for migration and invasion of cancer cells.
Mol Cancer Res. 3:183–194. 2005.PubMed/NCBI
|
11
|
Bell ES and Park M: Models of crk adaptor
proteins in cancer. Genes Cancer. 3:341–352. 2012. View Article : Google Scholar : PubMed/NCBI
|
12
|
Guo Y, Li S, Qu J, Wang S, Dang Y, Fan J,
Yu S and Zhang J: MiR-34a inhibits lymphatic metastasis potential
of mouse hepatoma cells. Mol Cell Biochem. 354:275–282. 2011.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Huang Y, Wang Q, Du Y, Bai L, Jin F, Zhang
J, Fan S, Wang H, Song L, Gao Y, et al: Inhibition of annexin A7
gene and protein induces the apotosis and decreases the invasion,
migration of the hepatocarcinoma cell line. Biomed Pharmacother.
68:819–824. 2014. View Article : Google Scholar : PubMed/NCBI
|
14
|
Zhang YH, Wang SQ, Sun CR, Wang M, Wang B
and Tang JW: Inhibition of JNK1 expression decreases migration and
invasion of mouse hepatocellular carcinoma cell line in vitro. Med
Oncol. 28:966–972. 2011. View Article : Google Scholar : PubMed/NCBI
|
15
|
Wu J, Meng J, Du Y, Huang Y, Jin Y, Zhang
J, Wang B, Zhang Y, Sun M and Tang J: RACK1 promotes the
proliferation, migration and invasion capacity of mouse
hepatocellular carcinoma cell line in vitro probably by PI3K/Rac1
signaling pathway. Biomed Pharmacother. 67:313–319. 2013.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Sleeman JP: The lymph node as a bridgehead
in the metastatic dissemination of tumors. Recent Results Cancer
Res. 157:55–81. 2000. View Article : Google Scholar : PubMed/NCBI
|
17
|
Kawada K and Taketo MM: Significance and
mechanism of lymph node metastasis in cancer progression. Cancer
Res. 71:1214–1218. 2011. View Article : Google Scholar : PubMed/NCBI
|
18
|
Kabilova TO, Kovtonyuk LV, Zonov EV,
Ryabchikova EI, Popova NA, Nikolin VP, Kaledin VI, Zenkova MA,
Vlassov VV and Chernolovskaya EL: Immunotherapy of hepatocellular
carcinoma with small double-stranded RNA. BMC Cancer. 14:3382014.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Abdel-Rahman O: Revisiting
oxaliplatin-based regimens for advanced hepatocellular carcinoma.
Curr Oncol Rep. 16:3942014. View Article : Google Scholar : PubMed/NCBI
|
20
|
Quetglas IM, Moeini A, Pinyol R and Llovet
JM: Integration of genomic information in the clinical management
of HCC. Best Pract Res Clin Gastroenterol. 28:831–842. 2014.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Chuang SC, La Vecchia C and Boffetta P:
Liver cancer: Descriptive epidemiology and risk factors other than
HBV and HCV infection. Cancer Lett. 286:9–14. 2009. View Article : Google Scholar : PubMed/NCBI
|
22
|
Shi J, Meng L, Sun MZ, Guo C, Sun X, Lin Q
and Liu S: CRKL knockdown promotes in vitro proliferation,
migration and invasion, in vivo tumor malignancy and lymph node
metastasis of murine hepatocarcinoma Hca-P cells. Biomed
Pharmacother. 71:84–90. 2015. View Article : Google Scholar : PubMed/NCBI
|
23
|
Lin Q, Sun MZ, Guo C, Shi J, Chen X and
Liu S: CRKL overexpression suppresses in vitro proliferation,
invasion and migration of murine hepatocarcinoma Hca-P cells.
Biomed Pharmacother. 69:11–17. 2015. View Article : Google Scholar : PubMed/NCBI
|
24
|
Liu S, Guo C, Wang J, Wang B, Qi H and Sun
MZ: ANXA11 regulates the tumorigenesis, lymph node metastasis and
5-fluorouracil sensitivity of murine hepatocarcinoma Hca-P cells by
targeting c-Jun. Oncotarget. 7:16297–16310. 2016.PubMed/NCBI
|
25
|
Hou L, Li Y, Jia YH, Wang B, Xin Y, Ling
MY and Lü S: Molecular mechanism about lymphogenous metastasis of
hepatocarcinoma cells in mice. World J Gastroenterol. 7:532–536.
2001. View Article : Google Scholar : PubMed/NCBI
|
26
|
Levin-Arama M, Abraham L, Waner T,
Harmelin A, Steinberg DM, Lahav T and Harlev M: Subcutaneous
compared with intraperitoneal KetamineXylazine for anesthesia of
mice. J Am Assoc Lab Anin Sci. 55:794–800. 2016.
|
27
|
Feliciello I and Chinali G: A modified
alkaline lysis method for the preparation of highly purified
plasmid DNA from Escherichia coli. Anal Biochem.
212:394–401. 1993. View Article : Google Scholar : PubMed/NCBI
|
28
|
Yamada S, Yanamoto S, Kawasaki G,
Rokutanda S, Yonezawa H, Kawakita A and Nemoto TK: Overexpression
of CRKII increases migration and invasive potential in oral
squamous cell carcinoma. Cancer Lett. 303:84–91. 2011. View Article : Google Scholar : PubMed/NCBI
|
29
|
Liu R, Wang Q, Xu G, Li K, Zhou L and Xu
B: The adaptor protein CrkII regulates IGF-1-induced biological
behaviors of pancreatic ductal adenocarcinoma. Tumour Biol.
37:817–822. 2016. View Article : Google Scholar : PubMed/NCBI
|
30
|
Askari M and Darabi M, Jahanzad E,
Mostakhdemian Hosseini Z, Musavi Chavoshi M and Darabi M:
Immunohistochemichal assessment of the CrkII proto-oncogene
expression in common malignant salivary gland tumors and
pleomorphic adenoma. J Dent Res Dent Clin Dent Prospects. 9:29–34.
2015. View Article : Google Scholar : PubMed/NCBI
|
31
|
Sun MZ, Liu S, Tang J, Wang Z, Gong X, Sun
C and Greenaway F: Proteomics analysis of two mice hepatocarcinoma
ascites syngeneic cell lines with high and low lymph node
metastasis rates provide potential protein markers for tumor
malignancy attributes to lymphatic metastasis. Proteomics.
9:3285–3302. 2009. View Article : Google Scholar : PubMed/NCBI
|
32
|
Klemke RL, Leng J, Molander R, Brooks PC,
Vuori K and Cheresh DA: CAS/Crk coupling serves as a ‘molecular
switch’ for induction of cell migration. J Cell Biol. 140:961–972.
1998. View Article : Google Scholar : PubMed/NCBI
|
33
|
Kiyokawa E, Hashimoto Y, Kurata T,
Sugimura H and Matsuda M: Evidence that DOCK180 up-regulates
signals from the CrkII-p130(Cas) complex. J Biol Chem.
273:24479–24484. 1998. View Article : Google Scholar : PubMed/NCBI
|